Hoge Stephen, President of an undisclosed company, has demonstrated a clear selling bias in his trading activity involving Moderna (MRNA) shares, according to SEC Form 4 filings. Over 27 reported transactions, Stephen has sold approximately $8.98 million worth of MRNA stock while purchasing just $3.06 million, resulting in a net divestment trend. His most significant sale occurred on February 23, 2026, when he disposed of shares valued at $7.81 million, supplemented by additional sales totaling over $3.06 million in subsequent days—including a $928,349 transaction on February 27, 2026. These disposals far outweigh his acquisition activity, which primarily consisted of smaller purchases under $100,000, such as a $99,180 buy on February 11, 2026.
Stephen’s trading has been exclusively concentrated in MRNA, with no activity in other securities. The pattern suggests a strategic reduction in his position, particularly given the absence of recent buys—his last recorded purchase was in February 2026, followed by multiple sales later that month. While some transactions involved modest acquisitions through derivative securities (coded "F"), the overwhelming majority of his recent activity has been outright sales (coded "S"). The lack of new buying activity in early 2026 reinforces the divestment trend, though the filings do not indicate whether these sales represent routine portfolio rebalancing or other financial planning. The data reflects a sustained shift away from MRNA holdings over time.
AI-assisted summary